The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type

Issue title: Second International Conference on Women and Societal Perspective on Quality of Life (WOSQUAL-2020)

Guest editors: Andi Nilawati Usman

Article type: Research Article

Authors: Miskad, Upik A.^a; | Rifai, Rizki A.^a | Masadah, Rina^a | Nelwan, Berti^a | Ahmad, Djumadi^a | Cangara, Husni^a | Prihantono, Prihantono^b | Zainuddin, Andi Alfian^c | Rahawarin, Halidah^a

Affiliations: [a] Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia | [b] Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia | [c] Department of Public Health & Family Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Correspondence: [*] Corresponding author: Upik A. Miskad, Department of Pathology Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. E-mail: upik.miskad@gmail.com

Abstract: BACKGROUND:The immune system is known to play an important role in tumor cell eradication. Although cancer cells were able to escape from the immune system, many studies showed mononuclear inflammatory cell infiltrates known as tumor-infiltrating lymphocytes (TILs) on breast cancer histopathology specimens showed better prognosis, including in disease-free survival (DFS) and chemotherapy responses. OBJECTIVE:This study aimed to reveal the predictive value of tumor-infiltrating lymphocytes (TILs) levels and CD8 expression in invasive breast carcinoma of no special type patients’ samples on response to anthracycline-based neoadjuvant chemotherapy. METHODS:75 pre-treatment biopsy samples that were diagnosed as invasive breast carcinoma of no special type were evaluated. TILs level determined following recommendations of International TILs Working Group 2014, CD8 expression assessed semiquantitatively after immunohistochemistry staining. Response to anthracycline-based neoadjuvant chemotherapy evaluated clinically using Response Evaluation Criteria in Solid Tumours (RECIST) criteria and pathologically by evaluating hematoxylin and eosin (H&E)-stained slides from mastectomy specimens after 3 or 4 cycles of neoadjuvant chemotherapy. RESULTS:Chi-squared analysis showed a significant relationship between TILs level and CD8 expression with chemotherapy responses clinically (p = 0.011 and p = 0.017 respectively) but not pathologically. Furthermore, the logistic regression test exhibit the predictive value of TILs level was 66.7% and CD8 expression was 64%. CONCLUSIONS:This study results suggest that TILs level and CD8 expression may be added as predictive factors to the response of anthracycline-based neoadjuvant chemotherapy, and oncologists may take benefit in breast cancer patient’s management.

Keywords: TILs, CD8, invasive breast carcinoma of no special type

DOI: 10.3233/BD-219002

Journal: Breast Disease, vol. 40, no. s1, pp. S9-S14, 2021